Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (129)	11/19/2006 3:34:30 PM
From: idos	Respond to of 210

"Are you saying I write incomprehensibly or that the abstracts I post are a challenge for you to understand?" Of course i meant that i have a problem understanding the scientific stuff but now after reading those links and some of the KOSN thread, i'm doing better. I usually get to read the boards late evening after work and my brain shuts down large parts of itself by then... Thanks for your post. idos

To: tuck who wrote (129)	11/19/2006 5:44:16 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 210

The course of treatment for refractory GIST is shorter than myeloma? fwiw, Infinity once listed in a press release Gleevec resistant GIST Herceptin resistant breast cancer Tarceva resistant lung cancer Velcade resistant multiple myeloma I am curious which trials would enroll the fastest. Maybe Perkins said what she said simply because Infinity has a partner in Medimmune, but Kosan does not. Just thinking out loud when what I really need to do is read your last ten posts again.